The therapeutic efficacy of LIFU was further validated in a subcutaneous xenograft tumor model, in which tumor size, survival rate and immunohistochemical changes were monitored.<h4>Results</h4>The results of the present study demonstrated that LIFU exerts anti-GBM effects by activating Piezo1 and modulating the downstream ATF3/PPP1r15a pathway to regulate apoptosis. The gene discussed is PPP1R15A; the disease is neoplasm.